Mark Sheptoff Financial Planning, LLC Fate Therapeutics Inc Transaction History
Mark Sheptoff Financial Planning, LLC
- $177 Million
- Q1 2025
A detailed history of Mark Sheptoff Financial Planning, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Mark Sheptoff Financial Planning, LLC holds 300 shares of FATE stock, worth $351. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300
Previous 300
-0.0%
Holding current value
$351
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding FATE
# of Institutions
158Shares Held
97.8MCall Options Held
45.8KPut Options Held
15.9K-
Redmile Group, LLC San Francisco, CA12.9MShares$15.1 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$12.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$11.8 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.38MShares$5.13 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.56MShares$4.16 Million0.15% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $113M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...